MAIA Biotechnology, Inc. (MAIA) has released an update.
MAIA Biotechnology, Inc. has initiated an at-the-market offering program, partnering with H.C. Wainwright & Co., LLC to sell shares of its stock with a potential total value of $1,445,000. The program allows sales to occur as the market permits, with Wainwright receiving a 3% commission on gross proceeds. This flexible offering structure is not an obligation for MAIA to sell, and can be suspended or terminated under certain conditions. The initiative is underpinned by a previously filed and effective shelf registration statement and is accompanied by a new prospectus supplement.
For further insights into MAIA stock, check out TipRanks’ Stock Analysis page.
